Table 4.
Outcomes in TIME; active versus placebo comparisons
| Measurement | Method of Measurement | ||||
|---|---|---|---|---|---|
| I. | CO-PRIMARY | ||||
| Δ Global LV Function | cMRI | ||||
| Δ Regional LV Function | cMRI | ||||
| II. | SECONDARY | ||||
| A. | Composite of : | ||||
| Death | Clinical outcome | ||||
| Reinfarction | Clinical outcome | ||||
| Repeat revascularization | Clinical outcome | ||||
| Hospitalization for HF | Clinical outcome | ||||
| B. | LV Mass* | cMRI | |||
| C. | LVEDV* | cMRI | |||
| D. | LVESV* | cMRI | |||
| E. | Infarct size | cMRI | |||
| III. |
Additional/ Subgroups |
Age, gender, race, hypertension history, diabetes mellitus, statin use, DES/BMS use MVO |
Baseline characteristic | ||
| cMRI | |||||